A functional polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, dysfunction, and ischemia: Data from the heart and soul study

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Farzaneh Far, Ramin ^a,b   Desir, Gary V ^c   Na, Beeya ^d   Schiller, Nelson B ^b   Whooley, Mary A ^b,d  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; ENZYME; GLUTAMIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RENALASE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING);

AGED; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEART DISEASE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS ECHOCARDIOGRAPHY; SYSTOLIC DYSFUNCTION; TREADMILL EXERCISE; CARDIOMEGALY; CHEMISTRY; GENETICS; MIDDLE AGED; PROSPECTIVE STUDY;

AGED; ASPARTIC ACID; CARDIOMEGALY; FEMALE; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; MYOCARDIAL ISCHEMIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 78149441930     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013496     Document Type: Article

References (36)

1. Peart WS (1977) The kidney as an endocrine organ. Lancet 2: 543-548.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305.
3. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, et al. (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295.
4. Joles JA, Koomans HA (2004) Causes and consequences of increased sympathetic activity in renal disease. Hypertension 43: 699-706.
5. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ (2004) Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 65: 1568-1576.
6. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, et al. (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725-1730.
7. Xu J, Li G, Wang P, Velazquez H, Yao X, et al. (2005) Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 115: 1275-1280.
8. Li G, Xu J, Wang P, Velazquez H, Li Y, et al. (2008) Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation 117: 1277-1282.
9. Xu J, Desir GV (2007) Renalase, a new renal hormone: its role in health and disease. Curr Opin Nephrol Hypertens 16: 373-378.
10. Desir GV (2008) Renalase deficiency in chronic kidney disease, and its contribution to hypertension and cardiovascular disease. Curr Opin Nephrol Hypertens 17: 181-185.
11. Ghosh SS, Krieg RJ, Sica DA, Wang R, Fakhry I, et al. (2008) Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system. Pediatr Nephrol.
12. Desir GV (2009) Regulation of blood pressure and cardiovascular function by renalase. Kidney Int 76: 366-370.
13. Zhao Q, Fan Z, He J, Chen S, Li H, et al. (2007) Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J Mol Med 85: 877-885.
14. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, et al. (2003) Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 290: 215-221.
15. Ren X, Ristow B, Na B, Ali S, Schiller NB, et al. (2007) Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease. Am J Cardiol 99: 1643-1647.
16. Schiller NB, Skioldebrand CG, Schiller EJ, Mavroudis CC, Silverman NH, et al. (1983) Canine left ventricular mass estimation by two-dimensional echocardiography. Circulation 68: 210-216.
17. Morris CK, Ueshima K, Kawaguchi T, Hideg A, Froelicher VF (1991) The prognostic value of exercise capacity: a review of the literature. Am Heart J 122: 1423-1431.
18. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, et al. (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2: 358-367.
19. Levey AS (1990) Measurement of renal function in chronic renal disease. Kidney Int 38: 167-184.
20. Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11: 127-152.
21. Tan AS, Berridge MV (2000) Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Methods 238: 59-68.
22. Didelez V, Sheehan N (2007) Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res 16: 309-330.
23. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566.
24. Vakili BA, Okin PM, Devereux RB (2001) Prognostic implications of left ventricular hypertrophy. Am Heart J 141: 334-341.
25. Turakhia MP, Schiller NB, Whooley MA (2008) Prognostic significance of increased left ventricular mass index to mortality and sudden death in patients with stable coronary heart disease (from the Heart and Soul Study). Am J Cardiol 102: 1131-1135.
26. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, et al. (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192.
27. Silberberg JS, Barre PE, Prichard SS, Sniderman AD (1989) Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36: 286-290.
28. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, et al. (2007) Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 298: 1291-1299.
29. Remme WJ (1998) The sympathetic nervous system and ischaemic heart disease. Eur Heart J 19 Suppl F: F62-F71.
30. Fonarow GC (2006) Beta-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations. Rev Cardiovasc Med 7: 1-9.
31. Kopecky SL (2006) Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol 98: 1115-1119.
32. Abrams J (2005) Clinical practice. Chronic stable angina. N Engl J Med 352: 2524-2533.
33. Abrams J, Thadani U (2005) Therapy of stable angina pectoris: the uncomplicated patient. Circulation 112: e255-e259.
34. Lunetta KL (2008) Genetic association studies. Circulation 118: 96-101.
35. Oh JK, Hatle L, Tajik AJ, Little WC (2006) Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 47: 500-506.
36. Coats AJ (2009) Ethical authorship and publishing. Int J Cardiol 131: 149-150.